Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Molecules 2013, 18(11), 13769-13811; doi:10.3390/molecules181113769
Review

The Janus Face of PAMAM Dendrimers Used to Potentially Cure Nonenzymatic Modifications of Biomacromolecules in Metabolic Disorders—A Critical Review of the Pros and Cons

1,* , 2,†
, 2,†
 and 2
Received: 1 July 2013; in revised form: 30 October 2013 / Accepted: 31 October 2013 / Published: 7 November 2013
(This article belongs to the Special Issue Dendrimers in Medicine and Biotechnology)
Download PDF [6376 KB, uploaded 18 June 2014]
Abstract: Diabetes mellitus, which is characterised by high blood glucose levels and the burden of various macrovascular and microvascular complications, is a cause of much human suffering across the globe. While the use of exogenous insulin and other medications can control and sometimes prevent various diabetes-associated sequelae, numerous diabetic complications are still commonly encountered in diabetic patients. Therefore, there is a strong need for safe and effective antihyperglycaemic agents that provide an alternative or compounding option for the treatment of diabetes. In recent years, amino-terminated poly(amido)amine (PAMAM) dendrimers (G2, G3 and G4) have attracted attention due to their protective value as anti-glycation and anti-carbonylation agents that can be used to limit the nonenzymatic modifications of biomacromolecules. The focus of this review is to present a detailed survey of our own data, as well as of the available literature regarding the toxicity, pharmacological properties and overall usefulness of PAMAM dendrimers. This presentation pays particular and primary attention to their therapeutic use in poorly controlled diabetes and its complications, but also in other conditions, such as Alzheimer’s disease, in which such nonenzymatic modifications may underlie the pathophysiological mechanisms. The impact of dendrimer administration on the overall survival of diabetic animals and on glycosylation, glycoxidation, the brain-blood barrier and cellular bioenergetics are demonstrated. Finally, we critically discuss the potential advantages and disadvantages accompanying the use of PAMAM dendrimers in the treatment of metabolic impairments that occur under conditions of chronic hyperglycaemia.
Keywords: PAMAM dendrimers; diabetes mellitus; hyperglycaemia; mitochondria function; bioenergetics; non-enzymatic glycosylation; diabetic markers; in vivo study PAMAM dendrimers; diabetes mellitus; hyperglycaemia; mitochondria function; bioenergetics; non-enzymatic glycosylation; diabetic markers; in vivo study
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Labieniec-Watala, M.; Karolczak, K.; Siewiera, K.; Watala, C. The Janus Face of PAMAM Dendrimers Used to Potentially Cure Nonenzymatic Modifications of Biomacromolecules in Metabolic Disorders—A Critical Review of the Pros and Cons. Molecules 2013, 18, 13769-13811.

AMA Style

Labieniec-Watala M, Karolczak K, Siewiera K, Watala C. The Janus Face of PAMAM Dendrimers Used to Potentially Cure Nonenzymatic Modifications of Biomacromolecules in Metabolic Disorders—A Critical Review of the Pros and Cons. Molecules. 2013; 18(11):13769-13811.

Chicago/Turabian Style

Labieniec-Watala, Magdalena; Karolczak, Kamil; Siewiera, Karolina; Watala, Cezary. 2013. "The Janus Face of PAMAM Dendrimers Used to Potentially Cure Nonenzymatic Modifications of Biomacromolecules in Metabolic Disorders—A Critical Review of the Pros and Cons." Molecules 18, no. 11: 13769-13811.


Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert